Beam Therapeutics (BEAM) investor relations material

Voting matters and shareholder proposals

• Election of three Class III director nominees for three-year terms ending at the 2029 annual meeting.

• Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory approval of named executive officer compensation (say-on-pay).

• Proxies may vote on other business arising at the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends voting for all three director nominees: John Evans, John Maraganore, Ph.D., and Christi Shaw.

• Directors to serve three-year terms if elected, expiring at the 2029 annual meeting.

Executive compensation and say-on-pay

• Advisory vote to approve compensation of named executive officers is included as a voting item.